BeiGene Ltd.
(NASDAQ : BGNE)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 0.73%69.480.0%$2231.74m
NVAXNovavax, Inc. -16.72%124.4899.2%$976.02m
SRNESorrento Therapeutics, Inc. -14.17%12.091.5%$643.59m
GILDGilead Sciences, Inc. 1.17%68.901.0%$573.21m
AMGNAmgen, Inc. 3.39%242.601.3%$489.15m
REGNRegeneron Pharmaceuticals, Inc. 2.92%616.372.7%$406.53m
VRTXVertex Pharmaceuticals, Inc. 3.38%270.721.9%$372.13m
BNTXBioNTech SE 1.51%69.480.0%$369.32m
BIIBBiogen, Inc. 1.66%294.761.6%$359.99m
ILMNIllumina, Inc. 0.94%344.413.5%$335.82m
VXRTVaxart, Inc. -15.35%9.100.0%$304.30m
ATNMActinium Pharmaceuticals, Inc. 0.74%9.7313.3%$238.44m
EBSEmergent BioSolutions, Inc. 5.35%128.886.4%$185.33m
ALXNAlexion Pharmaceuticals, Inc. 1.43%102.692.0%$167.27m
SGENSeattle Genetics, Inc. 3.19%158.386.2%$160.43m

Company Profile

BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.